DSCAM-AS1 and liver cancer: The importance of DSCAM-AS1 up-regulation in deterioration of patients’ outcome has been validated in independent studies in breast, lung, colorectal, skin, bone and liver cancers potentiating this lncRNA as a prognostic marker.